Citius Oncology, Inc. Cash Flow-to-Debt Ratio
Citius Oncology, Inc. cash flow-to-debt ratio. Citius Oncology, Inc. (CTOR) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2026, meaning its operating cash flow of $-2.85 Million could theoretically repay 0% of its total liabilities ($71.71 Million) in one year. Check CTOR cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Citius Oncology, Inc. (2022–2025)
Cash flow-to-debt ratio of Citius Oncology, Inc. from 2022 to 2025. Historical debt coverage capacity for Citius Oncology, Inc. across 4 annual periods. Check CTOR total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Citius Oncology, Inc. Cash Flow-to-Debt Ratio by Year (2022–2025)
Citius Oncology, Inc. cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Citius Oncology, Inc.. For the full cash flow conversion analysis, see CTOR cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | $-5.49 Million | $56.08 Million | ▼ -3063.2% |
| 2024 | 0.00x | $126.35K | $38.23 Million | ▲ +112.2% |
| 2023 | -0.03x | $-601.30K | $22.20 Million | ▼ -262.7% |
| 2022 | -0.01x | $-47.97K | $6.42 Million | — |